MAP2K7 and melanoma: Regardless, MEK inhibitors have emerged as an effective strategy to target drug resistant BRAFV600E melanomas in patients with or without previous exposure to BRAF inhibitors (Gilmartin et al., 2011; Wagle et al., 2011).